

Expert Second Opinion: Current and Future Roles of Immunotherapy and Targeted Therapy in the Management of Advanced Gastroesophageal Cancers — Microlearning Activity 4

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following adverse events (AEs) is a notable quality-of-life concern with oxaliplatin?
 - a. Hypertension
 - b. Insomnia
 - c. Peripheral neuropathy
2. The Phase III SPOTLIGHT and GLOW trials evaluated which targeted therapy in combination with chemotherapy for patients with untreated locally advanced unresectable or metastatic gastric and/or gastroesophageal junction adenocarcinoma?
 - a. Cetuximab
 - b. Trastuzumab deruxtecan
 - c. Zolbetuximab
3. Which of the following AEs has emerged as a possible side effect of zolbetuximab?
 - a. Alopecia
 - b. Gastritis
 - c. Interstitial lung disease
4. As part of the FOLFOX regimen, oxaliplatin confers a clinical benefit that is observed mainly during which period of treatment?
 - a. During the first 2 cycles
 - b. During the first 6 to 8 cycles
 - c. During the first 12 to 14 cycles